The Company is a distributor of video surveillance and access control equipment serving a customer base of security system integrators, alarm companies, access control and home automation installers, distributors and computers/electronics
stores. The company’s 900 accounts are distributed across Canada and the U.S.
About 87% of sales are to customers in Canada and 13% are to U.S. customers. Sales over the past four years have experienced strong double-digit growth, achieving a 3-year CAGR of 30%.
The Company is a global leader in the production, processing, and export of Specialty Crops to more than 150 customers in over 70 countries. Customers include cinema chains, distributors, wholesalers, snack factories and retail industries among others. The Company currently operates four product-based business units. Each of these units has separate storage and industrial processing facilities.
The Company maintains favorable supplier relationships with farmers who apply the best agronomic practices and meet the Company’s high standards of quality. The Company counts with modern technology to process the crops and access top market destinations that require BRC, GMO Free, and ISO standards.
In addition to exporting to new overseas markets such as China, Japan and others, the Company can develop new food specialties including peanuts, walnuts, pulses and others. Market consolidation is a key growth opportunity and the Company could lead the process.
Products sold are not commodities, price conditions are negotiated on trade shows and directly with customers. Global demand has been growing consistently over the years and volumes offered and product quality determine final price conditions. As a result of the quality of its products, the Company has a solid track record in achieving the best prices.
The Company is an FDA-registered Drug cGMP Labeler and Distributor operating across the U.S. The Company sells a select portfolio of, frequently prescribed medications to a proprietary network of independent pharmacies and distributors. The Company distributes directly to customers allowing participating pharmacies and distributors to realize higher margins when dispensing the products to patients. The business model also yields strong margins for the Company as well.
The Company has three exclusive agreements with drug manufacturers, and two additional exclusives are scheduled to launch during Q1 2018.
Sales have quadrupled since the Company’s inception just three years ago and achieved a 95% gross margin in 2017 with $13.8 million in adjusted EBITDA. Management expects sales to increase 62% and reach over $34.9 million in 2018 with more than $18.9 million in adjusted EBITDA.
Seeing an unmet need in the market, the Company developed a proprietary methodology of bringing commonly used products to market in a way that produces attractive margins for independent pharmacies. This is a high-margin, fast-growing business that is easy to scale and relocate. There is significant upside still ahead.
Management believes that the Company has created barriers to entry to help sustain market position and thwart competitive pressures. The Company’s proprietary method of product selection, exclusive distribution licenses and effective marketing strategies make it a unique growth platform within the biomedical supply chain. Management believes that it will continue to bring on two new products every 12 rolling months, at a minimum.